Mild to Moderate Atopic DermatitisNCT07166497
Evaluation of the Effect of the Product RV4660C CY0203 on Clinical, Biometrological and Biological Parameters in Adults With Mild to Moderate Atopic Dermatitis, an Exploratory Study
An observational study of Mild to Moderate Atopic Dermatitis, run by Pierre Fabre Dermo Cosmetique at 1 site in France.
Trial summary
In this exploratory study, we assessed the efficacy of a cosmetic product in adults suffering from mild to moderate atopic dermatitis. This exploratory study has been conducted as a monocentric non randomized study. Read more about this study
- Who is it for?
- Ages 18 years and older, women only
- Conditions the study is for
- Mild to Moderate Atopic Dermatitis
- What is being tested?
- Cosmetic product RV4660C CY0203
- How many people
- 21 participants
- Where
- 1 siteFrance
- Study dates
- 30 Oct 2023to 22 Dec 2023
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Women only
- No healthy volunteers
- Adult, Older adult
Study population: The study is disseminated to the database of potential subjects by email and, if needed, by telephone, describing study title,name(s), address(es) and contacts of the study site(s), name of the Principal Investigator, the parameter(s) in study, study inclusion and exclusion criteria, study objective(s), groups of treatment, namely, if experimental or comparative products are tested, potential risks of adverse events and study duration. The subjects that manifested interest in participating in the study might be contacted by telephone. Screening questions are asked in order to screen the main inclusion and exclusion criteria Subjects' answers to the telephonic recruitment are evaluated by the Principal Investigator who decides if the subject is to be selected for the recruitment visit.
Main inclusion criteria :
- Woman 18 years or older
- Non-menopausal woman
- Subject with phototype I, II, III, IV as classified by Fitzpatrick
- Subject with AD according to "The U.K. Working Party's Diagnostic Criteria for Atopic Dermatitis"
- Mild to moderate AD with SCORAD (SCORing Atopic Dermatitis) between 20 and 40 inclusive
- Subject who had at least 1 inflammatory AD flare-up in target areas in the year prior to inclusion visit
- Subject with at least one measuring target area on each upper or lower limb and defined as a typical AD flare-up area in the opinion of the subject
- Subject with at least one target area on each upper or lower limb with the following SCORAD target signs (between 3 and 18):
- Erythema ≥ 1
- Xerosis > 1
- Subject with pruritus intensity ≥ 3 on SCORAD analog visual scale (VAS)
Main non-inclusion criteria:
- Subject with superinfected AD
- Subject with a known history of allergy or intolerance to the components of the study product
- Subject with a dermatological condition other than AD, or characteristics (for example, tattoo) on the study areas, likely to interfere with the study evaluations according to the investigator's opinion
- Subject with another dermatological condition, acute or chronic pathology, or history of pathology, likely to interfere with study evaluations, or considered dangerous to the subject or incompatible with study requirements, in the opinion of the investigator
- Topical or oral treatment established or modified during the previous weeks or planned to be established or modified during the study, liable to interfere with the evaluation of the efficacy or cutaneous tolerance of the investigational product according to the investigator's assessment
Trial locations and contacts
1 site in 1 country.
About this study
In this exploratory study, we assessed the efficacy of a cosmetic product in adults suffering from mild to moderate atopic dermatitis. This exploratory study has been conducted as a monocentric non randomized study.
To perform this clinical study, 21 non menopausal women, aged from 18 years and older, suffering from mild to moderate atopic dermatitis were enrolled.
The subjects applied the investigational product once a day, in the evening on the whole body/ off face for up to 31 days.
4 visits were planned:
- Visit 1 - Day 1 - Inclusion visit
- Visit 2 - Day 8 - Intermediate visit
- Visit 3 - Day 29 (± 3 days) - Intermediate visit
- Visit 4 - Day 36 (± 3 days) - End of study visit
- Conditions
- Mild to Moderate Atopic Dermatitis
- Being tested
- Cosmetic product RV4660C CY0203
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Cosmetic product RV4660C CY0203Other
The product was applied once a day, in the evening, on the whole body/ off face on previously cleansed skin. The product was warmed in the hands before being applied in wide movements.
| Study group | Role | What they receive |
|---|---|---|
| Test Group | Not described Receives: Other: Cosmetic product RV4660C CY0203 |
What is being measured
The primary outcome is the main question the study is designed to answer.
Severity of atopic dermatitis throughout the body with SCORAD (SCOring Atopic Dermatitis)
Evaluation performed by the investigator of
- The extent of the disease using the rule of nines to estimate percentage of the affected body surface area. The maximum value for the extent of the disease is 100%.
- The disease intensity calculated based on six characteristics: erythema, edema, oozing/crusts, excoriations, lichenification, and dryness. Each characteristic is given a score between 0 and 3, where 0 is absent and 3 is severe. The scores for each characteristic are added together for a total intensity score of up to 18.
Evaluation performed by the subject of subjective symptoms including sleep loss and pruritus using a 10 cm visual analogue scale with a total maximum score of 20.
The SCORAD was then calculated with the following formula:
Extent/5 + 7×Intensity/2 + Subjective Symptoms
Measured: Before application and before wearing the connected watch (Day 1, Visit 1), after 7 consecutive days of wearing connected watch - before application (Day 8, Visit 2), after 21 (Day 29, Visit 3) and 28 (Day 36, Visit 4) consecutive days of application
Severity of the target atopic dermatitis areas (defined as a typical AD flare-up area in the opinion of the subject) with target SCORAD
Evaluation performed by the investigator of severity of the target areas calculated based on six characteristics: erythema, edema, oozing/crusts, excoriations, lichenification, and dryness. Each characteristic is given a score between 0 and 3, where 0 is absent and 3 is severe. The scores for each characteristic are added together for a total intensity score of up to 18.
Measured: Before application and before wearing the connected watch (Day 1, Visit 1), after 7 consecutive days of wearing connected watch - before application (Day 8, Visit 2), after 21 (Day 29, Visit 3) and 28 (Day 36, Visit 4) consecutive days of application
The pruritus severity with the Chronic itch burden scale over the past 7 days
Evaluation performed by the subject of pruritus severity on a NRS (0=no itching to 10=worst itching imaginable) over the past 7 days
Measured: Before application and before wearing the connected watch (Day 1, Visit 1), after 7 consecutive days of wearing connected watch - before application (Day 8, Visit 2), after 21 (Day 29, Visit 3) and 28 (Day 36, Visit 4) consecutive days of application
The impact of pruritus on quality of life with the Chronic itch burden scale over the past 7 days
Evaluation performed by the subject of the impact of pruritus on daily life over the past 7 days with 20 questions from 0=not at all, 1=a little, 2=somewhat, 3=a lot and 4=very much
Measured: Before application and before wearing the connected watch (Day 1, Visit 1), after 7 consecutive days of wearing connected watch - before application (Day 8, Visit 2), after 21 (Day 29, Visit 3) and 28 (Day 36, Visit 4) consecutive days of application
The pruritus severity with VAS (Visual Analog Scale) over the last 72 hours
Evaluation performed by the subject of pruritus severity using a VAS (continuous sliding scale from 0 cm = no itching to 10 cm = worst itching imaginable) over the last 72 hours using the SCORAD scale
Measured: Before application and before wearing the connected watch (Day 1, Visit 1), after 7 consecutive days of wearing connected watch - before application (Day 8, Visit 2), after 21 (Day 29, Visit 3) and 28 (Day 36, Visit 4) consecutive days of application
The pruritus severity with VAS (Visual Analog Scale) over the last 24 hours
Evaluation performed by the subject of pruritus severity using a VAS (continuous sliding scale from 0 cm = no itching to 10 cm = worst itching imaginable) over the last 24 hours
Measured: Before application and before wearing the connected watch (Day 1, Visit 1), after 7 consecutive days of wearing connected watch - before application (Day 8, Visit 2), after 21 (Day 29, Visit 3) and 28 (Day 36, Visit 4) consecutive days of application
The quality of sleep using connected watch
Measurement of sleep parameters using a connected watch worn on the wrist by the subjects
Measured: Before products' application from Day 1 to Day 7 and after 21 consecutive days of products' application from Day 8 to Day 29.
The quality of sleep with VAS (Visual Analog Scale)
Evaluation performed by the subject of quality of sleep using a VAS (continuous sliding scale from 0 cm = no sleep disturbance to 10 cm = worst sleep disturbance imaginable) over the last 72 hours using the SCORAD scale
Measured: Before application and before wearing the connected watch (Day 1, Visit 1), after 7 consecutive days of wearing connected watch - before application (Day 8, Visit 2), after 21 (Day 29, Visit 3) and 28 (Day 36, Visit 4) consecutive days of application
The quality of sleep with the Chronic itch burden scale
Evaluation performed by the subject of quality of sleep using the question n°4 from the Chronic Itch Burden Scale questionnaire
Measured: Before application and before wearing the connected watch (Day 1, Visit 1), after 7 consecutive days of wearing connected watch - before application (Day 8, Visit 2), after 21 (Day 29, Visit 3) and 28 (Day 36, Visit 4) consecutive days of application
The quality of sleep with the Sleep Health index
Evaluation performed by the subject of quality of sleep using the questions n°6 to 10 from the Sleep Health index
Measured: Before application and before wearing the connected watch (Day 1, Visit 1), after 7 consecutive days of wearing connected watch - before application (Day 8, Visit 2), after 21 (Day 29, Visit 3) and 28 (Day 36, Visit 4) consecutive days of application
The quality of sleep using Insomnia Severity Index (ISI) questionnaire
Evaluation performed by the subject of the quality of sleep
Measured: Before application and before wearing the connected watch (Day 1, Visit 1), after 7 consecutive days of wearing connected watch - before application (Day 8, Visit 2), after 21 (Day 29, Visit 3) and 28 (Day 36, Visit 4) consecutive days of application
The scratch using a connected watch
Measurement of scratch using a connected watch worn on the wrist by the subjects
Measured: Before products' application from Day 1 to Day 7 and after 21 consecutive days of products' application from Day 8 to Day 29.
The skin hydration using a Corneometer
Evaluation of the hydration index performed by a clinical research technician on one of the target area
Measured: Before application and before wearing the connected watch (Day 1, Visit 1), after 7 consecutive days of wearing connected watch - before application (Day 8, Visit 2), after 21 (Day 29, Visit 3) and 28 (Day 36, Visit 4) consecutive days of application
The skin barrier condition using a Vapometer
Evaluation of the trans-epidermal water loss performed by a clinical research technician on one of the target area
Measured: Before application and before wearing the connected watch (Day 1, Visit 1), after 7 consecutive days of wearing connected watch - before application (Day 8, Visit 2), after 21 (Day 29, Visit 3) and 28 (Day 36, Visit 4) consecutive days of application
The skin microbiota with non-invasive skin swabs
Evaluation of the skin microbiota performed by a clinical research technician on one of the target areas
Measured: Before product's application (Day 8, Visit 2) and after 28 consecutive days of product's application (Day 36, Visit 4)
Metabolites produced by host and microorganisms of the skin with non-invasive skin D-Squames
Evaluation of the metabolites produced by host and microorganisms of the skin performed by a clinical research technician on one of the target areas
Measured: Before product's application (Day 8, Visit 2) and after 28 consecutive days of product's application (Day 36, Visit 4)
Metabolites produced by host and microorganisms of the skin with non-invasive skin swabs
Evaluation of the metabolites produced by host and microorganisms of the skin performed by a clinical research technician on one of the target areas
Measured: Before product's application (Day 8, Visit 2) and after 28 consecutive days of product's application (Day 36, Visit 4)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Sep 2025
- Study start30 Oct 2023
- Primary completion22 Dec 2023
- Study completion22 Dec 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Mild to Moderate Atopic DermatitisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 21 participants (actual)
Sponsor and investigators
- Lead sponsor
- Pierre Fabre Dermo Cosmetique
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07166497
- Sponsor's protocol ID
- RV4660C20230530
- Status last verified
- Sep 2025
- First submitted
- 3 Sep 2025
- Last updated
- 10 Sep 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 10 Sep 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluation of the Effect of the Product RV4660C CY0203 on Clinical, Biometrological and Biological Parameters in Adults With Mild to Moderate Atopic Dermatitis, an Exploratory Study
- ClinicalTrials.gov ID
- NCT07166497
- Acronym / sponsor ID
- RV4660C20230530
- Conditions
- Mild to Moderate Atopic Dermatitis
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 21 participants (actual)
- Lead sponsor
- Pierre Fabre Dermo CosmetiqueIndustry (pharma, biotech, devices)
- Study start
- 30 Oct 2023 (actual)
- Primary completion
- 22 Dec 2023 (actual)
- Study completion
- 22 Dec 2023 (actual)
- First posted
- 10 Sep 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
In this exploratory study, we assessed the efficacy of a cosmetic product in adults suffering from mild to moderate atopic dermatitis. This exploratory study has been conducted as a monocentric non randomized study.
To perform this clinical study, 21 non menopausal women, aged from 18 years and older, suffering from mild to moderate atopic dermatitis were enrolled.
The subjects applied the investigational product once a day, in the evening on the whole body/ off face for up to 31 days.
4 visits were planned:
- Visit 1 - Day 1 - Inclusion visit
- Visit 2 - Day 8 - Intermediate visit
- Visit 3 - Day 29 (± 3 days) - Intermediate visit
- Visit 4 - Day 36 (± 3 days) - End of study visit
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Test Group | – | Other: Cosmetic product RV4660C CY0203 |
Who may qualify
- Ages
- 18 years and older
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- The study is disseminated to the database of potential subjects by email and, if needed, by telephone, describing study title,name(s), address(es) and contacts of the study site(s), name of the Principal Investigator, the parameter(s) in study, study inclusion and exclusion criteria, study objective(s), groups of treatment, namely, if experimental or comparative products are tested, potential risks of adverse events and study duration. The subjects that manifested interest in participating in the study might be contacted by telephone. Screening questions are asked in order to screen the main inclusion and exclusion criteria Subjects' answers to the telephonic recruitment are evaluated by the Principal Investigator who decides if the subject is to be selected for the recruitment visit.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Cosmetic product RV4660C CY0203The product was applied once a day, in the evening, on the whole body/ off face on previously cleansed skin. The product was warmed in the hands before being applied in wide movements. | Other | Test Group |
Primary outcome
Severity of atopic dermatitis throughout the body with SCORAD (SCOring Atopic Dermatitis)
Time frame: Before application and before wearing the connected watch (Day 1, Visit 1), after 7 consecutive days of wearing connected watch - before application (Day 8, Visit 2), after 21 (Day 29, Visit 3) and 28 (Day 36, Visit 4) consecutive days of application
Evaluation performed by the investigator of * The extent of the disease using the rule of nines to estimate percentage of the affected body surface area. The maximum value for the extent of the disease is 100%. * The disease intensity calculated based on six characteristics: erythema, edema, oozing/crusts, excoriations, lichenification, and dryness. Each characteristic is given a score between 0 and 3, where 0 is absent and 3 is severe. The scores for each characteristic are added together for a total intensity score of up to 18. Evaluation performed by the subject of subjective symptoms including sleep loss and pruritus using a 10 cm visual analogue scale with a total maximum score of 20. The SCORAD was then calculated with the following formula: Extent/5 + 7×Intensity/2 + Subjective Symptoms
Severity of the target atopic dermatitis areas (defined as a typical AD flare-up area in the opinion of the subject) with target SCORAD
Time frame: Before application and before wearing the connected watch (Day 1, Visit 1), after 7 consecutive days of wearing connected watch - before application (Day 8, Visit 2), after 21 (Day 29, Visit 3) and 28 (Day 36, Visit 4) consecutive days of application
Evaluation performed by the investigator of severity of the target areas calculated based on six characteristics: erythema, edema, oozing/crusts, excoriations, lichenification, and dryness. Each characteristic is given a score between 0 and 3, where 0 is absent and 3 is severe. The scores for each characteristic are added together for a total intensity score of up to 18.
The pruritus severity with the Chronic itch burden scale over the past 7 days
Time frame: Before application and before wearing the connected watch (Day 1, Visit 1), after 7 consecutive days of wearing connected watch - before application (Day 8, Visit 2), after 21 (Day 29, Visit 3) and 28 (Day 36, Visit 4) consecutive days of application
Evaluation performed by the subject of pruritus severity on a NRS (0=no itching to 10=worst itching imaginable) over the past 7 days
The impact of pruritus on quality of life with the Chronic itch burden scale over the past 7 days
Time frame: Before application and before wearing the connected watch (Day 1, Visit 1), after 7 consecutive days of wearing connected watch - before application (Day 8, Visit 2), after 21 (Day 29, Visit 3) and 28 (Day 36, Visit 4) consecutive days of application
Evaluation performed by the subject of the impact of pruritus on daily life over the past 7 days with 20 questions from 0=not at all, 1=a little, 2=somewhat, 3=a lot and 4=very much
The pruritus severity with VAS (Visual Analog Scale) over the last 72 hours
Time frame: Before application and before wearing the connected watch (Day 1, Visit 1), after 7 consecutive days of wearing connected watch - before application (Day 8, Visit 2), after 21 (Day 29, Visit 3) and 28 (Day 36, Visit 4) consecutive days of application
Evaluation performed by the subject of pruritus severity using a VAS (continuous sliding scale from 0 cm = no itching to 10 cm = worst itching imaginable) over the last 72 hours using the SCORAD scale
The pruritus severity with VAS (Visual Analog Scale) over the last 24 hours
Time frame: Before application and before wearing the connected watch (Day 1, Visit 1), after 7 consecutive days of wearing connected watch - before application (Day 8, Visit 2), after 21 (Day 29, Visit 3) and 28 (Day 36, Visit 4) consecutive days of application
Evaluation performed by the subject of pruritus severity using a VAS (continuous sliding scale from 0 cm = no itching to 10 cm = worst itching imaginable) over the last 24 hours
The quality of sleep using connected watch
Time frame: Before products' application from Day 1 to Day 7 and after 21 consecutive days of products' application from Day 8 to Day 29.
Measurement of sleep parameters using a connected watch worn on the wrist by the subjects
The quality of sleep with VAS (Visual Analog Scale)
Time frame: Before application and before wearing the connected watch (Day 1, Visit 1), after 7 consecutive days of wearing connected watch - before application (Day 8, Visit 2), after 21 (Day 29, Visit 3) and 28 (Day 36, Visit 4) consecutive days of application
Evaluation performed by the subject of quality of sleep using a VAS (continuous sliding scale from 0 cm = no sleep disturbance to 10 cm = worst sleep disturbance imaginable) over the last 72 hours using the SCORAD scale
The quality of sleep with the Chronic itch burden scale
Time frame: Before application and before wearing the connected watch (Day 1, Visit 1), after 7 consecutive days of wearing connected watch - before application (Day 8, Visit 2), after 21 (Day 29, Visit 3) and 28 (Day 36, Visit 4) consecutive days of application
Evaluation performed by the subject of quality of sleep using the question n°4 from the Chronic Itch Burden Scale questionnaire
The quality of sleep with the Sleep Health index
Time frame: Before application and before wearing the connected watch (Day 1, Visit 1), after 7 consecutive days of wearing connected watch - before application (Day 8, Visit 2), after 21 (Day 29, Visit 3) and 28 (Day 36, Visit 4) consecutive days of application
Evaluation performed by the subject of quality of sleep using the questions n°6 to 10 from the Sleep Health index
The quality of sleep using Insomnia Severity Index (ISI) questionnaire
Time frame: Before application and before wearing the connected watch (Day 1, Visit 1), after 7 consecutive days of wearing connected watch - before application (Day 8, Visit 2), after 21 (Day 29, Visit 3) and 28 (Day 36, Visit 4) consecutive days of application
Evaluation performed by the subject of the quality of sleep
The scratch using a connected watch
Time frame: Before products' application from Day 1 to Day 7 and after 21 consecutive days of products' application from Day 8 to Day 29.
Measurement of scratch using a connected watch worn on the wrist by the subjects
The skin hydration using a Corneometer
Time frame: Before application and before wearing the connected watch (Day 1, Visit 1), after 7 consecutive days of wearing connected watch - before application (Day 8, Visit 2), after 21 (Day 29, Visit 3) and 28 (Day 36, Visit 4) consecutive days of application
Evaluation of the hydration index performed by a clinical research technician on one of the target area
The skin barrier condition using a Vapometer
Time frame: Before application and before wearing the connected watch (Day 1, Visit 1), after 7 consecutive days of wearing connected watch - before application (Day 8, Visit 2), after 21 (Day 29, Visit 3) and 28 (Day 36, Visit 4) consecutive days of application
Evaluation of the trans-epidermal water loss performed by a clinical research technician on one of the target area
The skin microbiota with non-invasive skin swabs
Time frame: Before product's application (Day 8, Visit 2) and after 28 consecutive days of product's application (Day 36, Visit 4)
Evaluation of the skin microbiota performed by a clinical research technician on one of the target areas
Metabolites produced by host and microorganisms of the skin with non-invasive skin D-Squames
Time frame: Before product's application (Day 8, Visit 2) and after 28 consecutive days of product's application (Day 36, Visit 4)
Evaluation of the metabolites produced by host and microorganisms of the skin performed by a clinical research technician on one of the target areas
Metabolites produced by host and microorganisms of the skin with non-invasive skin swabs
Time frame: Before product's application (Day 8, Visit 2) and after 28 consecutive days of product's application (Day 36, Visit 4)
Evaluation of the metabolites produced by host and microorganisms of the skin performed by a clinical research technician on one of the target areas
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Sep 2025.
Related trials for Mild to Moderate Atopic Dermatitis
RecruitingPhase 2
A Study for AR100DP1 in Mild to Moderate Atopic Dermatitis
Dermatitis Atopic
Not yet recruitingPhase 2
To Evaluate the Safety and Efficacy of Hemay5394 in Patients With Mild to Moderate Atopic Dermatitis
Safety, Efficiency
Not yet recruitingPhase 2
A Study of JYP0066 Cream in Mild-to-Moderate Atopic Dermatitis
Atopic Dermatitis (AD)
Recruiting
Double-blind, Randomized, Non-inferiority Trial in Atopic Dermatitis: Comparison of Lipikar Balm and Relipid+ Balm in the Treatment of Mild to Moderate Atopic Dermatitis in Children and Adults
Atopic Dermatitis, Emollients
RecruitingPhase 2
A Study to Evaluate the Efficacy and Safety of IN-115314 Ointment in Mild to Moderate Atopic Dermatitis Adult Patients
Mild to Moderate Atopic Dermatitis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Mild to Moderate Atopic Dermatitis, run by Pierre Fabre Dermo Cosmetique at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 10 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Severity of atopic dermatitis throughout the body with SCORAD (SCOring Atopic Dermatitis) (time frame: Before application and before wearing the connected watch (Day 1, Visit 1), after 7 consecutive days of wearing connected watch - before application (Day 8, Visit 2), after 21 (Day 29, Visit 3) and 28 (Day 36, Visit 4) consecutive days of application). The study lists 17 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Sep 2025.